|
Sign In to gain access to subscriptions and/or personal tools.
|
Thienopyridine Therapy Influences Late Outcome After Coronary Stent Implantation
D. Aradi, MD,
A. Konyi, MD,
L. Palinkas, MD,
T. Berki, MD, PhD,
T. Pinter, MD,
T. Tahin, MD,
I. Horvath, MD,
L Papp, MD, DSc,
and
A. Komocsi, MD, PhD*
University of Pecs
* To whom correspondence should be addressed. E-mail: andras.komocsi{at}aok.pte.hu.
 |
Abstract |
|---|
Clinical significance of resistance to aspirin and thienopyridine therapy is poorly defined. The authors aimed to evaluate whether more effective antiplatelet therapy is associated with better outcome in patients on dualantiplatelet treatment. Using optical aggregometer, maximal platelet aggregation values were measured with induction of adenosine diphosphate, collagen, and adrenaline 30 ± 5 days after coronary stent implantation in 134 patients. Markers of platelet activation were also analyzed with fluorescent immunoassay in 57 patients. After 10 months of follow-up, 33 patients reached the composite endpoint of cardiovascular death, myocardial infarction, and revascularisation. Adenosine diphosphate-induced maximal aggregation values were in significant relationship with the development of major adverse cardiac events (P < .01). Level of soluble P-selectin proved to be an independent risk factor of adverse outcome (P< .05). As efficacy of thienopyridine therapy showed significant relation with clinical outcome, the authors conclude that interindividual variability in response to adenosine diphosphate-receptor antagonists may be of substantial clinical importance.
First published on April 2, 2008, doi:10.1177/0003319707304572
Angiology 2008;59:172.
A more recent version of this article appeared on May 1, 2008
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
